These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 10734160)
1. Selected cysteine residues in transmembrane domains of mu-opioid receptor are critical for effects of sulfhydryl reagents. Deng HB; Guang W; Wang JB J Pharmacol Exp Ther; 2000 Apr; 293(1):113-20. PubMed ID: 10734160 [TBL] [Abstract][Full Text] [Related]
2. Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. Zhang P; Johnson PS; Zöllner C; Wang W; Wang Z; Montes AE; Seidleck BK; Blaschak CJ; Surratt CK Brain Res Mol Brain Res; 1999 Oct; 72(2):195-204. PubMed ID: 10529478 [TBL] [Abstract][Full Text] [Related]
3. Delta and mu opioid receptors from the brain of a urodele amphibian, the rough-skinned newt Taricha granulosa: cloning, heterologous expression, and pharmacological characterization. Bradford CS; Walthers EA; Stanley DJ; Baugh MM; Moore FL Gen Comp Endocrinol; 2006 May; 146(3):275-90. PubMed ID: 16375901 [TBL] [Abstract][Full Text] [Related]
4. Functional significance of cysteine residues in the delta opioid receptor studied by site-directed mutagenesis. Ehrlich GK; Andria ML; Zheng X; Kieffer B; Gioannini TL; Hiller JM; Rosenkranz JE; Veksler BM; Zukin RS; Simon EJ Can J Physiol Pharmacol; 1998 Mar; 76(3):269-77. PubMed ID: 9673790 [TBL] [Abstract][Full Text] [Related]
5. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor. Minami M; Nakagawa T; Seki T; Onogi T; Aoki Y; Katao Y; Katsumata S; Satoh M Mol Pharmacol; 1996 Nov; 50(5):1413-22. PubMed ID: 8913373 [TBL] [Abstract][Full Text] [Related]
6. Opioid peptide receptor studies. 7. The methylfentanyl congener RTI-4614-4 and its four enantiomers bind to different domains of the rat mu opioid receptor. Lu YF; Xu H; Liu-Chen LY; Chen C; Partilla JS; Brine GA; Carroll FI; Rice KC; Lai J; Porreca F; Sadee W; Rothman RB Synapse; 1998 Feb; 28(2):117-24. PubMed ID: 9450512 [TBL] [Abstract][Full Text] [Related]
7. The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors. Xu W; Chen C; Huang P; Li J; de Riel JK; Javitch JA; Liu-Chen LY Biochemistry; 2000 Nov; 39(45):13904-15. PubMed ID: 11076532 [TBL] [Abstract][Full Text] [Related]
8. Binding properties of C-truncated delta opioid receptors. Wang CH; Zhou DH; Chen J; Li GE; Pei G; Chi ZQ Zhongguo Yao Li Xue Bao; 1997 Jul; 18(4):337-40. PubMed ID: 10072917 [TBL] [Abstract][Full Text] [Related]
9. Opioid peptide receptor studies, 11: involvement of Tyr148, Trp318 and His319 of the rat mu-opioid receptor in binding of mu-selective ligands. Xu H; Lu YF; Partilla JS; Zheng QX; Wang JB; Brine GA; Carroll FI; Rice KC; Chen KX; Chi ZQ; Rothman RB Synapse; 1999 Apr; 32(1):23-8. PubMed ID: 10188634 [TBL] [Abstract][Full Text] [Related]
11. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain. Chaipatikul V; Loh HH; Law PY J Pharmacol Exp Ther; 2003 Jun; 305(3):909-18. PubMed ID: 12626655 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and pharmacological studies of new hybrid derivatives of fentanyl active at the mu-opioid receptor and I2-imidazoline binding sites. Dardonville C; Fernandez-Fernandez C; Gibbons SL; Ryan GJ; Jagerovic N; Gabilondo AM; Meana JJ; Callado LF Bioorg Med Chem; 2006 Oct; 14(19):6570-80. PubMed ID: 16797997 [TBL] [Abstract][Full Text] [Related]
13. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. Zhao GM; Qian X; Schiller PW; Szeto HH J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366 [TBL] [Abstract][Full Text] [Related]
14. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints. Fowler CB; Pogozheva ID; Lomize AL; LeVine H; Mosberg HI Biochemistry; 2004 Dec; 43(50):15796-810. PubMed ID: 15595835 [TBL] [Abstract][Full Text] [Related]
15. Ligand selectivity of cloned human and rat opioid mu receptors. Rothman RB; Xu H; Wang JB; Partilla JS; Kayakiri H; Rice KC; Uhl GR Synapse; 1995 Sep; 21(1):60-4. PubMed ID: 8525463 [TBL] [Abstract][Full Text] [Related]
16. Opioid peptide receptor studies. 16. Chronic morphine alters G-protein function in cells expressing the cloned mu opioid receptor. Xu H; Lu YF; Rothman RB Synapse; 2003 Jan; 47(1):1-9. PubMed ID: 12422367 [TBL] [Abstract][Full Text] [Related]
17. Sulfhydryl groups on opioid receptors revisited. Evidence for two sulfhydryl groups at or near the active site of the mu opioid receptor. Ofri D; Simon EJ Receptor; 1992; 2(2):109-19. PubMed ID: 1335327 [TBL] [Abstract][Full Text] [Related]
19. Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor. Holleran BJ; Domazet I; Beaulieu ME; Yan LP; Guillemette G; Lavigne P; Escher E; Leduc R Biochem Pharmacol; 2009 Apr; 77(8):1374-82. PubMed ID: 19426676 [TBL] [Abstract][Full Text] [Related]
20. Cysteine-scanning mutagenesis and thiol modification of the Rickettsia prowazekii ATP/ADP translocase: evidence that transmembrane regions I and II, but not III, are structural components of the aqueous translocation channel. Alexeyev MF; Roberts RA; Daugherty RM; Audia JP; Winkler HH Biochemistry; 2004 Jun; 43(22):6995-7002. PubMed ID: 15170337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]